KR20000073752A - A process for preparing substituted Bezoa complex - Google Patents

A process for preparing substituted Bezoa complex Download PDF

Info

Publication number
KR20000073752A
KR20000073752A KR1019990017223A KR19990017223A KR20000073752A KR 20000073752 A KR20000073752 A KR 20000073752A KR 1019990017223 A KR1019990017223 A KR 1019990017223A KR 19990017223 A KR19990017223 A KR 19990017223A KR 20000073752 A KR20000073752 A KR 20000073752A
Authority
KR
South Korea
Prior art keywords
solution
gallbladder
bilirubin
alternative
sulfur
Prior art date
Application number
KR1019990017223A
Other languages
Korean (ko)
Other versions
KR100318415B1 (en
Inventor
이성수
Original Assignee
이성수
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이성수 filed Critical 이성수
Priority to KR1019990017223A priority Critical patent/KR100318415B1/en
Publication of KR20000073752A publication Critical patent/KR20000073752A/en
Application granted granted Critical
Publication of KR100318415B1 publication Critical patent/KR100318415B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G9/00—Cultivation in receptacles, forcing-frames or greenhouses; Edging for beds, lawn or the like
    • A01G9/24—Devices or systems for heating, ventilating, regulating temperature, illuminating, or watering, in greenhouses, forcing-frames, or the like
    • A01G9/241—Arrangement of opening or closing systems for windows and ventilation panels
    • A01G9/242—Arrangement of opening or closing systems for windows and ventilation panels for greenhouses with flexible coverings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G9/00—Cultivation in receptacles, forcing-frames or greenhouses; Edging for beds, lawn or the like
    • A01G9/14—Greenhouses
    • A01G9/1407—Greenhouses of flexible synthetic material
    • A01G9/1415—Greenhouses of flexible synthetic material with double or multiple walls

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE: A preparation method for alternative bezoar bovis containing bilirubin extracted from the gall bladder of cattle or pig is provided. The alternative bezoar bovis includes bilirubin, which shows the same efficacy as original bezoar bovis, of more than 70-170 % compared with the bezoar bovis. CONSTITUTION: An alterative bezoar bovis is prepared by the following steps of : (a) obtaining the solution of gall bladder from cattle or a pig using NaHSO3; (b) alkalizing the resulted solution with NaOH; (c) boiling the solution at more than 100°C for more than 30 minutes, followed by cooling this to 25-30°C; (d) diluting and stirring the cooled solution with CHCl3; (e) mixing and stirring this in HCl solution; (f) leaving the mixed solution to obtain a precipitate that is a main component of the alternative oriental bezoar; (g) pressing and extracting the precipitate under the pressure reduction and isolating the fraction containing bilirubin by silicagel chromatography; and (h) washing and pressed drying this.

Description

대체 우황의 제조(추출) 방법{A process for preparing substituted Bezoa complex}A process for preparing substituted Bezoa complex

본 발명은 소 또는 돼지의 쓸개에서 추출된 빌리루빈을 함유하는 대체우황의 추출(제조)방법에 관한 것으로, 더욱 상세하기는 우황 표준 품에 비해 빌리루빈의 함량이 70∼170% 이상 함유된 대체우황 및 이의 추출방법에 관한 것이다.The present invention relates to a method for extracting (manufacturing) alternative cows containing bilirubin extracted from the gallbladder of cattle or pigs, and more specifically, alternative cows containing 70-170% or more of bilirubin in comparison with the standard cow cows and It relates to a method of extraction thereof.

천연 우황은 일반적으로 담낭염에 걸린 소의 쓸개를 건조하여 사용하는 것으로, 실제적으로 그 희소가치 때문에 상당히 고가의 제품이다. 이러한 우황은 일반적으로 우황청심환으로 알려진 뇌졸중, 고혈압, 동맥경화증, 자율신경실조증 등의 치료제의 원료로 주로 사용되고 있으며, 그 외 일반적인 감기약 제조에도 사용하는 등 그 용도는 다양하다. 우리 나라의 경우 우황청심환의 함량은 우황 45mg에 대해 산약 263mg, 감초 188mg, 인삼 94mg, 포황 94mg, 신곡 94mg, 대두황권 66mg, 계피 66mg, 아교 66mg, 작약 56mg, 맥문동 56mg, 황금 56mg, 당귀 56mg, 방풍 56mg, 백출 56mg, 시호 47mg, 길경 47mg, 행인 47mg, 복령 47mg, 천공 47mg, 영양각 38mg, 사향 38mg, 용뇌 38mg, 백렴 28mg 및 건강 17mg으로 구성되어 있으며, 이러한 우황의 주요성분은 빌리루빈으로서 우황의 적량을 위해서는 일정한 빌리루빈의 함량을 요구하고 있다.Natural sulfur is generally used to dry the gallbladder of cows with cholecystitis, which is actually very expensive because of its rare value. Such sulfur is commonly used as a raw material for the treatment of stroke, hypertension, arteriosclerosis, autonomic ataxia, and the like, which are commonly known as blue sulfur cheongsimhwan, and other uses such as general cold medicine manufacture. In the case of Korea, the content of wohwang cheongsimhwan is about 263 mg of powdered milk, licorice 188mg, ginseng 94mg, turmeric 94mg, new song 94mg, soybean yellow soybean 66mg, cinnamon 66mg, glue 66mg, peony 56mg, macmundong 56mg, golden 56mg, donkey 56mg, windproof It consists of 56mg, baekchul 56mg, shiho 47mg, gilyeong 47mg, pedestrian 47mg, bokyeong 47mg, perforation 47mg, nutrition angle 38mg, musk 38mg, cephalopod 38mg, pneumonia 28mg and health 17mg. To require a certain amount of bilirubin.

따라서 본 발명은 우황과 동일한 약효성분인 빌리루빈을 우황표준품 대비 70∼170% 함유하고 있는 대체우황을 개발함으로써 낮은 가격으로 우황대용품을 공급하고 일반인에게 우황과 동일한 약효를 지닌 대체우황을 제공하는 데 있다.Therefore, the present invention provides a substitute for cow's milk at a low price by providing an alternative cow's milk containing 70-170% of bilirubin, which is the same active ingredient as cow's milk, and providing a substitute cow with the same potency as cow's milk. .

본 발명의 대체우황은 그 함량 면에서 우황표준품보다 우수할 뿐만 아니라 독성 면에서도 안정한 물질로써 향후 우황을 대체시킬 수 있는 물질로 이용이 가능한 것이다.The alternative sulfur of the present invention is not only superior to the standard of sulfur in terms of its content, but also can be used as a material that can replace the sulfur in the future as a stable substance in terms of toxicity.

도 1은 본 발명의 대체우황 획분 WO-1의 HPLC 데이터를 나타낸 도면이다.1 is a diagram showing the HPLC data of the alternative sulfur fraction WO-1 of the present invention.

도 2는 빌리루빈 표준 품의 HPLC 데이터를 나타낸 도면이다.2 is a diagram showing HPLC data of a bilirubin standard.

※ 도면 부호 설명※ Explanation of Drawings

1 : 20분에서 23분 사이의 대체우황 획분 피크1: 20-23 minute alternative sulfur fraction peak

2 : 46분에서 48분 사이의 대체우황 획분 피크2: alternate sulfur fraction peak between 46 and 48 minutes

3 : 67분에서 69분 사이의 대체우황 획분 피크3: alternate sulfur fraction peak between 67 and 69 minutes

100 중량부의 소나 돼지의 쓸개를 추출한 후 표피를 세척하고, 아황산수소나트륨(NaHSO3)에 4∼6배양의 물을 가한 용액을 이용하여 소나 돼지의 쓸개를 세척한 후, 쓸개 표피를 제거하여 쓸개 액을 수득하고, 수득된 쓸개 액에 수산화나트륨을 가하여 알칼리화 시킨 후, 쓸개 액을 100℃ 이상으로 30분 이상 끓이고, 끓인 액을 냉각기에 넣어 25∼30℃까지 냉각시키고, 이 냉각액에 클로로포름(CHCl3)을 넣어 완전희석 교반시킨 후 용기에 담아둔다.After extracting the gallbladder of 100 parts by weight of cow or pig, wash the epidermis, wash the gallbladder of the cow or pig using a solution of 4-6 cultures of sodium bisulfite (NaHSO 3 ), then remove the gallbladder epidermis A solution was obtained, and sodium hydroxide was added to the obtained gallbladder solution to make it alkaline, and then the gallbladder solution was boiled at 100 ° C. or more for 30 minutes or more, the boiled solution was put in a cooler and cooled to 25-30 ° C., and the chloroform (CHCl) 3 ) Put it in complete dilution and put it in a container.

염산을 1 : 5의 비율로 물에 용해시키고, 이 염산 액을 용기에 담아둔 쓸개 액에 넣어 혼합 교반하고, 이 혼합액을 23∼27℃에서 18∼23분동안 방치하면 본 발명의 대체우황 주성분이 침전하게 된다. 침전물을 감압 하에서 클로로포름(CHCl3)의 성분이 완전해소 될 때까지 농축시키고, 실리카겔 크로마토그래피를 이용하여 빌리루빈 성분을 분리시킨다. 이때 사용되는 실리카겔크로마토그래피는 용출액으로 에탄올과 메틸아세테이트 혼합용매를 사용하며, 크로마토그래피 분리시 주성분인 빌리루빈이 검출되며, 이는 빌리루빈 표준 품과 비교하여 알 수 있다. 이때 얻어진 획분을 WO-1 이라 명명하였고, 이 획분을 감압 건조시키면 본 발명의 대체우황을 얻을 수 있다.When hydrochloric acid is dissolved in water at a ratio of 1: 5, the hydrochloric acid solution is added to a gallbladder liquid in a container, mixed and stirred, and the mixed solution is left at 23 to 27 ° C for 18 to 23 minutes, whereby the main alternative sulfur component of the present invention is used. This will precipitate. The precipitate is concentrated under reduced pressure until the component of chloroform (CHCl 3 ) is completely dissolved and the bilirubin component is separated using silica gel chromatography. In this case, silica gel chromatography used is a mixed solvent of ethanol and methyl acetate as the eluent, bilirubin is detected as a main component during chromatography separation, which can be seen in comparison with the bilirubin standard. The fraction obtained at this time was named WO-1, and the alternative sulfur of the present invention can be obtained by drying the fraction under reduced pressure.

본 발명의 대체우황 획분 WO-1의 HPLC 데이터와 표준 품 빌리루빈의 HPLC 데이터를 비교하여 본 발명의 대체우황 성분의 확인시험을 행한다. 시험조건은 파마시아사에서 제조된 HPLC를 사용하고, 용출액으로 에탄올과 메틸아세테이트 1 : 1의 혼합용매를 사용하고, HPLC 상의 압력조건은 약 70mmHg 감압 하에서 수행하며, 획분 콜렉터는 96-웰 플레이트 콜렉터를 사용하였다.Alternative sulfur fraction of the present invention The HPLC data of WO-1 and the standard bilirubin HPLC data are compared to confirm the alternative sulfur component of the present invention. Test conditions were carried out using HPLC prepared by Pharmacia, using a mixed solvent of ethanol and methyl acetate 1: 1 as the eluent, pressure conditions on HPLC was carried out under about 70mmHg reduced pressure, the fraction collector was a 96-well plate collector Used.

시험 후 대체우황 획분 WO-1의 HPLC 획분의 피크는 약 20분에서 23분 사이에 을 얻을 수 있었으며, 또한 46분에서 48분 사이에 또다른 획분과 67분에서 69분 사이에 또다른 획분을 얻을 수 있었다. 이때 나타난 HPLC 데이터는 도 1과 같다. 한편 빌리루빈 표준 품의 HPLC 데이터는 도 2와 같다. 도 2에서 46분에서 48분 사이에 피크가 나타나는 것으로 보아 대체우황 획분 WO-1의 두 번째 획분이 빌리루빈임을 확인하였다.After testing, the peaks of the HPLC fractions of WO-1 could be obtained between 20 and 23 minutes, and between 46 and 48 minutes and another fraction between 67 and 69 minutes. Could get The HPLC data shown here is shown in FIG. 1. Meanwhile, HPLC data of the bilirubin standard is shown in FIG. 2. From the peaks appearing between 46 and 48 minutes in FIG. 2, it was confirmed that the second fraction of the alternative sulfur fraction WO-1 was bilirubin.

또한 본 발명의 대체우황의 조성을 더욱 확실히 확인하기 위하여 GPC분석을 한 바, 본 발명의 대체우황은 약 20∼28%의 당, 15∼18%의 빌리루빈, 30∼45%의 단백질로 구성되어 있었으며, 단백질의 아미노산 정량분석 결과는 다음과 같다.In addition, GPC analysis was conducted to more clearly confirm the composition of the alternative sulfur of the present invention. The alternative sulfur of the present invention was composed of about 20 to 28% sugar, 15 to 18% bilirubin, and 30 to 45% protein. The results of amino acid quantification of proteins are as follows.

단백질 내 주요 아미노산 분포는 페닐알라닌 10%, 아이소류신 8%, 시스테인 8%, 프롤린 5% 및 발린 5% 등이었다.The major amino acid distributions in the protein were 10% phenylalanine, 8% isoleucine 8%, cysteine 8%, proline 5% and valine 5%.

이하 실시예에서 본 발명을 상세히 설명하면 다음과 같다. 그러나 이러한 실시예들로 본 발명의 범위를 한정하는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to the following Examples. However, these examples do not limit the scope of the present invention.

(실시예 1) 본 발명의 대체우황 획분 WO-1의 분리Example 1 Isolation of Alternative Sulfur Fraction WO-1 of the Present Invention

소나 돼지의 쓸개를 10kg 추출한 후 표피를 세척하고, 아황산수소나트륨(NaHSO3)에 4∼6배양의 물을 가한 용액 5L를 이용하여 소나 돼지의 쓸개를 세척한 후, 쓸개 표피를 제거하여 쓸개 액 1.2L를 수득하고, 수득된 쓸개 액에 10% 수산화나트륨 용액 1L를 가하여 알칼리화 시킨 후, 쓸개 액을 100℃ 이상으로 45분간 끓이고, 끓인 액을 냉각기에 넣어 25∼30℃까지 냉각시키고, 이 냉각액에 클로로포름(CHCl3) 0.5ℓ를 넣어 완전희석 교반시킨 후 용기에 담아둔다.Extract 10 kg of gallbladder from bovine or swine, wash the epidermis, wash the gallbladder of bovine or swine using 5L solution of 4-6 cultures of sodium bisulfite (NaHSO 3 ), and then remove the gallbladder epidermis. 1.2 L was obtained, and 1 L of 10% sodium hydroxide solution was added to the gallbladder solution, which was alkalized, and the gallbladder was boiled at 100 DEG C or more for 45 minutes, and the boiled liquid was put in a cooler to cool to 25 to 30 DEG C. 0.5 liters of chloroform (CHCl 3 ) was added to the mixture and stirred in a container.

20% 염산수용액을 1ℓ에 용해시키고, 이 염산 액을 용기에 담아둔 쓸개 액에 넣어 혼합 교반하고, 이 혼합액을 25℃에서 20분 동안 방치하면 본 발명의 대체우황 주성분이 침전하게 된다. 침전물을 감압 하에서 농축시키고, 실리카겔 크로마토그래피를 이용하여 빌리루빈 성분을 포함한 획분을 분리시킨다. 이때 사용되는 실리카겔크로마토그래피는 용출액으로 에탄올과 메틸아세테이트 혼합용매를 사용하며, 크로마토그래피 분리시 주성분인 빌리루빈이 검출되며, 이때 얻어진 획분을 WO-1 이라 명명하였고, 이 획분을 감압 건조시키면 본 발명의 대체우황을 얻을 수 있다.20% aqueous hydrochloric acid solution is dissolved in 1 L, the hydrochloric acid solution is mixed and stirred in the gallbladder liquid contained in the container, and the mixed solution is left at 25 ° C. for 20 minutes to precipitate the main substitute sulfur main ingredient of the present invention. The precipitate is concentrated under reduced pressure and the fraction containing the bilirubin component is separated using silica gel chromatography. In this case, the silica gel chromatography used is a mixed solvent of ethanol and methyl acetate as the eluent, bilirubin is detected as a main component during chromatographic separation, and the fraction obtained at this time is named WO-1, and the fraction is dried under reduced pressure. You can get a replacement cow.

(실시예 2) 급성 독성시험Example 2 Acute Toxicity Test

본 발명의 대체우황 WO-1을 6주령의 스프레이돌리 마우스를 이용하여 LD50를 측정하였다. 측정결과 본 발명의 대체우황 WO-1의 LD50치는 1,230mg/kg 이었다. 따라서 본 발명의 대체우황은 일반적 우황의 LD50치인 950mg/kg 보다 큰 수치를 나타내어 더욱 안전한 화합물로 인식되었다.The alternative sulfur WO-1 of the present invention was measured LD50 using 6-week-old Spray Dolly mice. As a result of measurement, the LD 50 value of the substitute sulfur WO-1 of the present invention was 1,230 mg / kg. Therefore, Calculus Bovis alternative of the present invention is represented by the LD 50 hit by 950mg / kg of the number greater than Calculus Bovis were generally recognized as safer compounds.

(실시예 3) 빌리루빈 함량 실험Example 3 Bilirubin Content Experiment

빌리루빈 함량 실험은 HPLC를 이용하여 시험하였다. 본 발명의 대체우황 획분 WO-1의 두 번째 피크인 46분에서 48분의 함량은 전체 용출액 량의 약 15∼18%에 해당하였다. 나머지 부분의 함량은 당 및 단백질로 구성되어 있음을 GPC 분석을 통하여 확인하였다.Bilirubin content experiments were tested using HPLC. The content of 46 minutes to 48 minutes, the second peak of the alternative sulfur fraction WO-1 of the present invention, corresponded to about 15-18% of the total amount of the eluate. The content of the remaining portion was confirmed by GPC analysis consisting of sugar and protein.

(실시예 4) 유효성 실험Example 4 Effectiveness Experiment

대체우황으로 우황청심환을 제조하여 일반 환자 10명에게 투여하였다(1군). 우황으로 우황청심환을 제조하여 일반 환자 10명에게 투여하였다(2군). 우황을 넣지 않고 나머지 성분만으로 우황청심환을 제조하여 일반 환자 10명에게 투여하였다(3군). 각 군의 유효한 효과를 수치로 나타낸 바, 0점(효과 없음), 1점(약간 효과 있음), 2점(효과 있음), 3점(효과 매우 우수함) 각 1,2,3군의 약효 유효성 실험 결과는 1군 2.1±0.5, 2군 2.3±0.4, 3군 0.5±0.5로서 대체우황을 투여한 군의 경우 우황을 투여한 군에 비해 약 90% 이상의 효과를 나타내었으나, 우황을 투여하지 않은 3군의 경우 우황을 투여한 군에 비해 약 20% 정도만의 효과를 나타냄으로써 본원발명의 대체우황의 유효성을 입증케 되었다.Woohwang Cheongsimhwan was prepared as alternative milk and administered to 10 general patients (Group 1). Whey blue cheongsimhwan was prepared with cow sulfur and administered to 10 general patients (group 2). Whey blue cheongsimhwan was prepared using only the remaining ingredients without adding whey and administered to 10 general patients (group 3). The effective effects of each group were expressed numerically: 0 points (no effect), 1 point (with some effect), 2 points (with effect), 3 points (excellent effect) The experimental results were 2.1 ± 0.5 in group 1, 2.3 ± 0.4 in group 2, and 0.5 ± 0.5 in group 3, which showed more than 90% of the effects of the alternative sulfur group compared with the group treated with the sulfur group. In the case of group 3, only about 20% of the effects of the sulfur-treated group showed the effectiveness of the alternative sulfur of the present invention.

(실시예 5) 안정성 실험Example 5 Stability Experiment

본 발명의 대체우황 획분 WO-1의 안정성 실험을 위해 25℃, 75% 습도 하에서 1개월, 3개월, 6개월의 경시변화를 관찰하였다. 경시변화의 관찰은 대체우황 획분 내의 빌리루빈 함량의 감소 여부를 측정하였다. 1개월, 3개월 후의 경우 빌리루빈 함량의 감소는 발견되지 않았으나, 6개월 후의 경우 약 0.8% 정도의 함량의 경시변화가 관찰되었다. 그러나 이와 같은 경시변화는 통상적인 약물의 경시변화에 비교하여 안정한 것으로 충분히 의약품으로 대체할 수 있는 것으로 판정되었다.For the stability experiment of the alternative sulfur fraction WO-1 of the present invention, changes over time of 1 month, 3 months and 6 months were observed under 25 ° C. and 75% humidity. Observation of the change over time measured the decrease in the bilirubin content in the alternative sulfur fraction. After 1 month and 3 months, there was no decrease in bilirubin content, but after 6 months there was about 0.8% change over time. However, this change over time is stable compared to the change over time of conventional drugs, it was determined that it can be sufficiently replaced by the drug.

본 발명의 효과는 우황과 동일한 약효성분인 빌리루빈을 우황표준품 대비 70∼120% 함유하고 있는 대체우황을 개발함으로써 낮은 가격으로 우황대용품을 공급하고 일반인에게 우황과 동일한 약효를 지닌 대체우황을 제공하는 데 있다. 본 발명의 대체우황은 그 함량 면에서 우황표준품보다 더 우수할 뿐만 아니라 독성 면에서도 안정한 물질로써 향후 우황을 대체시킬 수 있는 물질로 이용이 가능한 것이다.The effect of the present invention is to provide a substitute for cow's milk at a low price by providing alternative cows containing 70-120% of bilirubin, which is the same active ingredient as cow's milk, to provide a substitute cow with the same efficacy as cow's milk. have. The alternative sulfur of the present invention is not only superior to the standard of sulfur in terms of its content but also stable in terms of toxicity, and can be used as a material that can replace sulfur in the future.

Claims (2)

소나 돼지의 쓸개를 추출한 후 표피를 세척하고, 아황산수소나트륨(NaHSO3)에 4∼6배양의 물을 가한 용액을 이용하여 소나 돼지의 쓸개를 세척한 후, 쓸개 표피를 제거하여 쓸개 액을 수득하고, 수득된 쓸개 액에 수산화나트륨을 가하여 알칼리화 시킨 후, 쓸개 액을 100℃ 이상으로 30분 이상 끓이고, 끓인 액을 냉각기에 넣어 25∼30℃까지 냉각시키고, 이 냉각액에 클로로포름(CHCl3)을 넣어 완전희석 교반시킨 후, 염산을 1 : 5의 비율로 물에 용해시키고, 이 염산 액을 용기에 담아둔 쓸개 액에 넣어 혼합 교반하고, 이 혼합액을 23∼27℃에서 18∼23분 동안 방치된 침전물을 감압 하에서 농축시키고, 실리카겔 크로마토그래피를 이용하여 빌리루빈 성분을 함유하는 대체우황 획분을 분리시킨 후, 감압 건조시켜 대체우황의 추출방법After extracting the gallbladder of cows or pigs, wash the epidermis, wash the gallbladders of cows or pigs using a solution of 4 to 6 cultures of sodium bisulfite (NaHSO 3 ), and then remove the gallbladder epidermis to obtain a gallbladder solution Then, sodium hydroxide was added to the obtained gallbladder solution to make it alkaline, and then the gallbladder solution was boiled at 100 DEG C or more for 30 minutes or more, the boiled liquid was put in a cooler to cool to 25-30 DEG C, and chloroform (CHCl 3 ) was added to the cooling liquid. After complete dilution and stirring, hydrochloric acid was dissolved in water at a ratio of 1: 5, the hydrochloric acid solution was added to a gallbladder liquid in a container, mixed and stirred, and the mixed solution was left at 23 to 27 ° C for 18 to 23 minutes. The precipitates were concentrated under reduced pressure, and the replacement sulfur fraction containing bilirubin was separated by silica gel chromatography, followed by drying under reduced pressure to extract the replacement sulfur. 제 1항에 있어서, 실리카겔크로마토그래피는 용출액으로 에탄올과 메틸아세테이트 혼합용매를 사용하며, 크로마토그래피 분리시 주성분인 빌리루빈이 검출되는 획분을 수득함을 특징으로 하는 대체우황의 추출방법.The method of claim 1, wherein silica gel chromatography uses a mixed solvent of ethanol and methyl acetate as the eluent, and obtains a fraction in which bilirubin, a main component, is detected during chromatography separation.
KR1019990017223A 1999-05-13 1999-05-13 A process for preparing substituted Bezoa complex KR100318415B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019990017223A KR100318415B1 (en) 1999-05-13 1999-05-13 A process for preparing substituted Bezoa complex

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019990017223A KR100318415B1 (en) 1999-05-13 1999-05-13 A process for preparing substituted Bezoa complex

Publications (2)

Publication Number Publication Date
KR20000073752A true KR20000073752A (en) 2000-12-05
KR100318415B1 KR100318415B1 (en) 2001-12-22

Family

ID=19585384

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019990017223A KR100318415B1 (en) 1999-05-13 1999-05-13 A process for preparing substituted Bezoa complex

Country Status (1)

Country Link
KR (1) KR100318415B1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050049632A (en) * 2003-11-22 2005-05-27 주식회사 씨메드 Method of sus scrofa domestica gall
CN102944640A (en) * 2012-11-27 2013-02-27 哈药集团中药二厂 Quality control method of AngongNiuhuangShuan
CN116392509A (en) * 2023-06-08 2023-07-07 内蒙古为旭生物科技有限公司 Method for inducing cow to form bezoar

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277625A (en) * 1985-06-04 1986-12-08 Osaka Chem Lab Method for producing 'go-oh' from living cattle
CN85108577A (en) * 1985-11-23 1987-06-03 谢静波 The manufacture method of artificial Calculus Bovis
CN87107251A (en) * 1987-12-02 1988-09-14 董学武 The direct bilirubinic method of rapid extraction
CN1041105A (en) * 1988-09-12 1990-04-11 河北农业大学 Cultivate the production technology of natural Calculus Bovis
KR960021034A (en) * 1994-12-02 1996-07-18 김동현 Manufacturing method of cow sulfur

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050049632A (en) * 2003-11-22 2005-05-27 주식회사 씨메드 Method of sus scrofa domestica gall
CN102944640A (en) * 2012-11-27 2013-02-27 哈药集团中药二厂 Quality control method of AngongNiuhuangShuan
CN116392509A (en) * 2023-06-08 2023-07-07 内蒙古为旭生物科技有限公司 Method for inducing cow to form bezoar

Also Published As

Publication number Publication date
KR100318415B1 (en) 2001-12-22

Similar Documents

Publication Publication Date Title
Girgih et al. Evaluation of the in vitro antioxidant properties of a cod (Gadus morhua) protein hydrolysate and peptide fractions
Yan et al. Influence of phenolic compounds on physicochemical and functional properties of protein isolate from Cinnamomum camphora seed kernel
JP5538611B2 (en) Maillard reaction inhibitor
Xingfei et al. Properties of ACE inhibitory peptide prepared from protein in green tea residue and evaluation of its anti-hypertensive activity
CN104968360B (en) For treatment and/or nursing skin, the compound and their make-up and beauty or pharmaceutical composition of hair and/or mucous membrane
KR101736775B1 (en) Cosmetic composition for improving skin wrinkle containing Rubus coreanus extract
Dash et al. Proteolytic and antioxidant activity of protein fractions of seeds of Cucurbita moschata
JP3502415B2 (en) Maillard reaction inhibitor
CN103547254B (en) Containing the wrinkle improvement compositions from the composition of Placenta Hominis
Tutor et al. Angiotensin-converting enzyme inhibition of fractions from Eleusine indica leaf extracts
KR100318415B1 (en) A process for preparing substituted Bezoa complex
CN105267268A (en) Ginseng leaf extractive manufacturing method and cosmetic composition comprising ginseng leaf extractive serving as effective ingredient
JP2005281284A (en) Skin care preparation for external use for promoting collagen synthesis
Ajisafe et al. Snail mucus from Achatina fulica as a biomaterial exhibits pro-survival effects on human chondrocytes
JPS59101413A (en) Hair-protecting cosmetic composition compounded with tannin
JPH09208431A (en) Hair tonic having promoting action on growth of hair papilla cell
JP3533392B1 (en) External preparation for skin
KR101535410B1 (en) Compositions containing an extract of a Primula denticulata and use thereof
Meding et al. Allergic contact dermatitis from diphenylthiourea in Vulkan heat retainers
CN108186440A (en) Can antibiotic skin-care Chinese medicinal plant shower cream and its preparation method and application
Sharma et al. Recent Advancements in Novel Bioactive Peptides and Protein Hydrolysates Isolated from Different Medicinal Plants Along with Their Applications in Food and Pharmaceutical Industries
CN108210440A (en) A kind of toner based on pilose antler extracting solution and preparation method thereof
CN108938709B (en) Water extract of tobacco bean and application thereof
Ruth et al. Free radical scavenging-related antioxidant properties and inhibitory activities of Telfairia occidentalis seed protein hydrolysates and peptide fractions against two key enzymes implicated in diabetes mellitus
CN113968896B (en) Application of small peptide in preparation of osteoarthritis treatment drug

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20111212

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee